THERAPEUTIC SOLID DOSAGE FORMS

(19)

(11)

EP 4 149 460 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	08.01.2025 Bulletin 2025/02

(45)	Mention of the grant of the patent:
	27.11.2024 Bulletin 2024/48

(21)	Application number: 21725377.2

(22)	Date of filing: 13.05.2021

(51)

International Patent Classification (IPC):

A61K 31/4045^(2006.01)
A61P 25/22^(2006.01)
A61P 25/30^(2006.01)
A61K 9/16^(2006.01)
A61K 9/48^(2006.01)
A61P 25/00^(2006.01)

A61P 25/18^(2006.01)
A61P 25/24^(2006.01)
C07D 209/16^(2006.01)
A61K 9/20^(2006.01)
A61K 45/06^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61P 25/00; C07D 209/16; A61K 9/2009; A61K 9/2013; A61K 9/2027; A61K 9/2059; A61K 9/485; A61K 9/4858; A61K 9/4866; A61K 31/4045; A61K 45/06; A61P 25/18; A61P 25/22; A61P 25/24; A61P 25/30

	C-Sets:
	A61K 31/4045, A61K 2300/00;

(86)	International application number:
	PCT/EP2021/062794

(87)	International publication number:
	WO 2021/244831 (09.12.2021 Gazette 2021/49)

(54)	THERAPEUTIC SOLID DOSAGE FORMS FESTE THERAPEUTISCHE DARREICHUNGSFORMEN FORMES GALÉNIQUES SOLIDES THÉRAPEUTIQUES

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

02.06.2020 WO PCT/EP2020/065244
02.06.2020 GB 202008303
02.06.2020 US 202016890664
01.12.2020 GB 202018950
01.12.2020 GB 202018955
01.12.2020 US 202017108679
01.12.2020 US 202017108938
22.03.2021 GB 202103981
22.03.2021 US 202117208583
23.04.2021 WO PCT/EP2021/060750

(43)	Date of publication of application:
	22.03.2023 Bulletin 2023/12

(60)	Divisional application:
	24215587.7

(73)	Proprietor: Cybin UK Ltd
	London EC1Y 8RT (GB)

(72)	Inventors:
	RANDS, Peter London EC2A 4BX (GB) BENWAY, Tiffanie London EC2A 4BX (GB) JOEL, Zelah London EC2A 4BX (GB) LAYZELL, Marie London EC2A 4BX (GB) JAMES, Ellen London EC2A 4BX (GB)

(74)	Representative: Patent Boutique LLP
	10A Printing House Yard Hackney Road London E2 7PR London E2 7PR (GB)

(56)

References cited: :

WO-A1-2019/081764

WO-A1-2020/245133

SIMON D. BRANDT ET AL: "Microwave-accelerated synthesis of psychoactive deuterated N , N -dialkylated-[ [alpha] , [alpha] , [beta] , [beta] -d 4 ]-tryptamines", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 51, no. 14, 1 November 2008 (2008-11-01), GB, pages 423 - 429, XP055724013, ISSN: 0362-4803, DOI: 10.1002/jlcr.1557
MORRIS ET AL.: "Indolealkylamine metabolism: Synthesis of deuterated indolealkylamines as metabolic probes", JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, vol. 33, no. 6, 1993, pages 455 - 465, XP009522345, DOI: 10.1002/jlcr.2580330603
BEATON J M ET AL: "A comparison of the behavioral effects of proteo- and deutero-N, N-dimethyltryptamine", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, ELSEVIER, US, vol. 16, no. 5, 1 May 1982 (1982-05-01), pages 811 - 814, XP023806754, ISSN: 0091-3057, DOI: 10.1016/0091-3057(82)90240-4

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).